BLOG
New DEA Guidance On Quantitative Thresholds
Guidance On Quantitative Thresholds Written-by: Deneen Fumich, RPh As the Pharmaceutical Supply Chain continues to digest the Injunctive Relief requirements for the Big 3 Wholesalers, questions have been posed by industry to both the DEA and State Regulators as to the...
Recent Articles
NABP DDA: New Process & “Ineligibility Matrix”
A PBM audit often invokes a great sense of dread by all the pharmacy’s employees but especially for the pharmacy owner. In 2020, the average PBM...
Imminent Approval of Psilocybin
Imminent Approval of Psilocybin In the last few years, we have seen a flurry of research activity and momentum building for psilocybin treatments to...
The Increasing Trend of Drug Price Transparency
The Increasing Trend of Drug Price Transparency There are presently nineteen states with drug price transparency laws, and an additional ten more...
Top 5 Mistakes Pharmacies Make During URAC Accreditation
Top 5 Mistakes Pharmacies Make During URAC Accreditation navigating clients through URAC accreditation, I've found the most problematic areas for...
MDMA in Phase 3 Trials for FDA Approval
MDMA in Phase 3 Trials for FDA Approval Phase 3 trials are already underway for MDMA as treatment for PTSD. The effort is spearheaded by MAPS, who...
NABP Accused of Enforcing ‘Shadow Regulation’ Twice in 3 years
NABP Accused of Enforcing ‘Shadow Regulation’ Twice in 3 years NABP is a private organization that mostly earns revenue by offering various services...
